Orthotopic Heart Transplantation through Minimally Invasive Approach

2007 ◽  
Vol 15 (5) ◽  
pp. 446-448 ◽  
Author(s):  
Jose L Navia ◽  
Eric E Roselli ◽  
Fernando A Atik ◽  
Gonzalo V Gonzalez-Stawinski ◽  
Nicholas G Smedira
Keyword(s):  
Minimally Invasive ◽  
Heart Transplantation ◽  
Orthotopic Heart Transplantation ◽  
Cardiac Transplant ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Invasive Approach ◽  
End Stage ◽  
Invasive Techniques

Minimal access approaches are a trend in cardiothoracic surgery. Gained experience in these minimally invasive techniques have allowed its application to more complicated procedures, such as heart transplantation. Both classic and bicaval techniques of cardiac transplant were performed through a partial lower sternotomy in 10 end-stage heart failure patients with no previous cardiac surgery. The procedure was considered safe with adequate exposure, minimal postoperative pain medication requirements, acceptable operative times, and good long-term outcome.

Heart transplantation

2019 ◽  
pp. 165-182
Author(s):  
Finn Gustafsson ◽  
Kasper Rossing
Keyword(s):  
Heart Transplantation ◽  
Conventional Treatment ◽  
Immunosuppressive Drugs ◽  
Pharmacological Therapy ◽  
Cardiac Allograft ◽  
Term Outcome ◽  
Long Term Outcome ◽  
End Stage Heart Failure ◽  
End Stage

Heart transplantation remains the treatment of choice for end-stage heart failure refractory to conventional treatment. Long-term outcome is excellent, and median survival currently exceeds 13 years. The main causes of death late after transplantation are cardiac allograft vasculopathy and cancer. Medical therapy after transplantation is complex, including immunosuppressive therapy to reduce the risk of graft rejection and prophylaxis against viral and protozoal infections, as well as adjunctive therapy to treat common comorbidities, for instance hypertension. Pharmacological therapy of comorbid conditions requires specific consideration to clinically important interactions with immunosuppressive drugs.

Heart transplantation

2019 ◽  
pp. 165-182
Author(s):  
Finn Gustafsson ◽  
Kasper Rossing
Keyword(s):  
Heart Transplantation ◽  
Conventional Treatment ◽  
Immunosuppressive Drugs ◽  
Pharmacological Therapy ◽  
Cardiac Allograft ◽  
Term Outcome ◽  
Long Term Outcome ◽  
End Stage Heart Failure ◽  
End Stage

Heart transplantation remains the treatment of choice for end-stage heart failure refractory to conventional treatment. Long-term outcome is excellent, and median survival currently exceeds 13 years. The main causes of death late after transplantation are cardiac allograft vasculopathy and cancer. Medical therapy after transplantation is complex, including immunosuppressive therapy to reduce the risk of graft rejection and prophylaxis against viral and protozoal infections, as well as adjunctive therapy to treat common comorbidities, for instance hypertension. Pharmacological therapy of comorbid conditions requires specific consideration to clinically important interactions with immunosuppressive drugs.

Long-term outcome of orthotopic heart transplantation in Asians: An analysis of the United Network of Organ Sharing database

2020 ◽  
Vol 39 (11) ◽  
pp. 1315-1318
Author(s):  
Shun Kohsaka ◽  
Yasuhiro Shudo ◽  
Hanjay Wang ◽  
Bharathi Lingala ◽  
Masataka Kawana ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Orthotopic Heart Transplantation ◽  
Term Outcome ◽  
Long Term Outcome ◽  
United Network

scholarly journals Should We Consider Patients with Coexistent Hepatitis B or C Infection for Orthotopic Heart Transplantation?

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Baskar Sekar ◽  
Pippa J. Newton ◽  
Simon G. Williams ◽  
Steven M. Shaw
Keyword(s):  
Heart Failure ◽  
Hepatitis B ◽  
Heart Transplantation ◽  
Advanced Heart Failure ◽  
Viral Reactivation ◽  
Orthotopic Heart Transplantation ◽  
Hepatitis C Infection ◽  
Term Outcome ◽  
Long Term Outcome

Heart transplantation (HTX) is the gold standard surgical treatment for patients with advanced heart failure. The prevalence of hepatitis B and hepatitis C infection in HTX recipients is over 10%. Despite its increased prevalence, the long-term outcome in this cohort is still not clear. There is a reluctance to place these patients on transplant waiting list given the increased incidence of viral reactivation and chronic liver disease after transplant. The emergence of new antiviral therapies to treat this cohort seems promising but their long-term outcome is yet to be established. The aim of this paper is to review the literature and explore whether it is justifiable to list advanced heart failure patients with coexistent hepatitis B/C infection for HTX.

Long term outcome after heterotopic heart transplantation

2011 ◽  
Vol 59 (S 01) ◽  
Author(s):  
J Sindermann ◽  
I Alejnik ◽  
J Hoffmann ◽  
S Klotz ◽  
A Löher ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Heterotopic Heart Transplantation

Biopsy-Negative Rejection Late after Heart Transplantation: Impact on Long-Term Outcome

2019 ◽  
Vol 38 (4) ◽  
pp. S287-S288
Author(s):  
A. Wolfson ◽  
M. Kittleson ◽  
J. Patel ◽  
E. Kransdorf ◽  
R. Cole ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Term Outcome ◽  
Long Term Outcome
Sign in / Sign up

Export Citation Format

Share Document